►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".
►►Very important notification on publication fee
Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.
Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
Author Benefits
● Easy submission via online system
● Efficient and professional peer review
● Rapid pre-print online publication
● No charge for publication and open access
● International visibility-All full texts are free in PubMed Central
Announcements
Publication of the 3rd issue in 2020 |
|
As a highlighted public health event, coronavirus disease (COVID-19) pandemic affects people’s routine life globally this year. For cancer patients with COVID-19, it seems very important to study their risks, clinical features, therapeutics, medical cares, and so on. Prof. Xiaoping Miao and Xiaojiang Cui contribute an editorial and a review on this topic respectively. We believe these two papers could be as the important references for both clinicians and researchers worldwide.
In this issue, several papers on basic researches focus the roles of some molecules in the tumorigenesis and cancer development, such as CMTM family proteins, Anoctamin 7 (ANO7), PRAS40, SHP2. What’s more, reviews and original researches on clinical oncology could be attractive as well to readers. The contents refer to management strategy for papillary thyroid microcarcinoma, immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients, patients treated with SVILE vs. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type, and other aspects.
We hope this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine. |
|
| Posted: 2020-08-14 | |
New impact factor: 5.432 |
|
According to the Journal Citation Reports (2020), the Impact Factor (2019) of Cancer Biology & Medicine is 5.432, locating in Q1 areas of both Medicine, Research & Experimental category (ranking 20/138) and Oncology category (ranking 52/244). As a peer-reviewed open-access journal, Cancer Biology & Medicine is quarterly published by China Anti-Cancer Association and Tianjin Medical University Cancer Institute and Hospital. It focuses on translational cancer research, dedicating to narrowing the gap between bench and bedside. Except for SCIE, the journal has been indexed in PubMed/ PubMed Central, BIOSIS Previews, SCOPUS, DOAJ, and Chemical Abstracts. Meanwhile, it is also a member of the Committee on Publication Ethics (COPE) and CrossRef. Welcome to submit your work to Cancer Biology & Medicine and communicate with your colleagues worldwide via our platform. 
|
|
| Posted: 2020-06-30 | |
| More Announcements... |
Vol 17, No 2: May 2020
Table of Contents
Review
| ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance | |
| Wanjiru Muriithi, Lucy Wanjiku Macharia, Carlos Pilotto Heming, et al. | 253-269 |
| Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression | |
| Xiaofan Wei, Hongquan Zhang | 270-281 |
| Role of the mechanical microenvironment in cancer development and progression | |
| Qiuping Liu, Qing Luo, Yang Ju, et al. | 282-292 |
| Triple negative breast cancer: special histological types and emerging therapeutic methods | |
| Lu Cao, Yun Niu | 293-306 |
| Magnetic resonance imaging-guided and targeted theranostics of colorectal cancer | |
| Yanan Li, Jingqi Xin, Yongbing Sun, et al. | 307-327 |
Original Article
| CDK11 negatively regulates Wnt/β-catenin signaling in the endosomal compartment by affecting microtubule stability | |
| Danmin Ou, Lin Chen, Jiang He, et al. | 328-342 |
| Heat shock protein 47 promotes tumor survival and therapy resistance by modulating AKT signaling via PHLPP1 in colorectal cancer | |
| Yijye Chern, Peter Zhang, Hyelim Ju, et al. | 343-356 |
| CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma | |
| Ting Li, Si Wu, Lei Jia, et al. | 357-370 |
| KIF18B promotes tumor progression in osteosarcoma by activating β-catenin | |
| Tian Gao, Ling Yu, Zhiwei Fang, et al. | 371-386 |
| DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors | |
| Yangling Li, Dongmei Zhou, Shuang Xu, et al. | 387-400 |
| Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development | |
| Qi Wang, Qin Tang, Lijun Zhao, et al. | 401-417 |
| Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling | |
| Xiaoling Zhang, Yan Zhang, Yanan Jia, et al. | 418-432 |
| Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab | |
| Chao Yang, Yanli Tan, Hongzhao Qi, et al. | 433-443 |
| Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer | |
| Juan Moreno-Rubio, Santiago Ponce, Rosa Álvarez, et al. | 444-457 |
| Identification of novel Lynch syndrome mutations in Chinese patients with endometriod endometrial cancer | |
| Caixia Ren, Yan Liu, Yuxiang Wang, et al. | 458-467 |
| Value of metabolic parameters in distinguishing primary mediastinal lymphomas from thymic epithelial tumors | |
| Lei Zhu, Xiaofeng Li,, Jian Wang, et al | 468-477 |
| Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis | |
| Hongcai Yang, Yi Yang, Jianping Dou, et al. | 478-491 |
| Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications | |
| Xiaofei Zhu, Di Chen, Yangsen Cao, et al. | 492-500 |
| Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy | |
| Zhichao Liao, Ting Li, Chao Zhang, et al | 501-512 |
Erratum
| Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients | |
| Xingsheng Hu, Dongyong Yang, Yalun Li, et al. | 513 |
OUR FRIENDS
